Breast Cancer Research and Treatment

, Volume 64, Issue 2, pp 165–176 | Cite as

Preliminary Assessment of Cognitive Function in Breast Cancer Patients Treated with Tamoxifen

  • Annlia Paganini-Hill
  • Linda J. Clark


Background. Tamoxifen is an anti-estrogen used in the treatment of breast cancer and to reduce the incidence of breast cancer in high risk women. Although the brain is an estrogen target organ and several studies have found a beneficial effect of estrogen on cognitive function, the effect of tamoxifen on cognition has not been reported. Therefore, we initiated a follow-up study of women who had participated in a study of breast cancer to assess the effect of tamoxifen treatment on cognitive function.

Methods. We recruited previously interviewed patients who were cases in a population-based case-control study of 2,653 women with primary breast cancer diagnosed between 1987 and 1996 at ages 55–72 years in Los Angeles County, California, USA. In November 1997, each case was mailed a follow-up questionnaire. Cognitive function was assessed by (1) clock drawing, (2) copying a box drawing, and (3) narrative writing to describe a pictured scene. Women reporting treatment with tamoxifen were categorized as standard-term users (4–5 years), short-term users (<4 years) or long-term users (6 + years) and compared to never users. Tamoxifen users were also classified as past or current users. Differences in the mean cognitive test scores were tested after adjusting for age, age at diagnosis, stage of disease, radiation therapy, chemotherapy, race, education, marital status, previous use of oral contraceptives, type of menopause, age at last menstrual period, previous use of hormone replacement therapy, and depressive symptoms using analysis of covariance. All p-values for differences in the proportion of women who had errors on the tests are 2-sided and adjusted for age, stage of disease at diagnosis, and chemotherapy.

Findings. Information from 1,163 women aged 57–75 years of age was analyzed; 710 had taken tamoxifen. There was little difference between women who had used tamoxifen for the standard five years and never users on the three cognitive tests. However, more women who had used tamoxifen for the standard term reported seeing their physician for memory problems than non-users (3.8% vs 1.5%, p = 0.04). This was especially true for current users of standard-term (8.0%, p = 0.003). Current users also had a significantly lower mean complexity score (p = 0.03) on the narrative writing task. No differences were seen between past users and non-users.

Interpretation. Our study suggests that current use of tamoxifen may adversely effect cognition. Further study of tamoxifen and cognition is needed so that healthy women considering tamoxifen for the primary prevention of breast cancer have comprehensive information about the side effects of the treatment.

cognitive function memory tamoxifen 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Forbes JF: The control of breast cancer: the role of tamoxifen. Semin Oncol 24(Suppl 1): S1-5–S1-19, 1997Google Scholar
  2. 2.
    Fisher B, Costantino JP, Wickerman DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90: 1371–1388, 1998PubMedGoogle Scholar
  3. 3.
    Haskell SG, Richardson ED, Horwitz RI: The effect of estrogen replacement therapy on cognitive function in women: a critical review of the literature. J Clin Epid 50: 1249–1264, 1997Google Scholar
  4. 4.
    Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA 279: 688–695, 1998PubMedGoogle Scholar
  5. 5.
    Love RR, Cameron L, Connell BL, Leventhal H: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 151: 1842–1847, 1991PubMedGoogle Scholar
  6. 6.
    Ross RK, Paganini-Hill A, Wan PC, Pike MC: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 328–332, 2000PubMedGoogle Scholar
  7. 7.
    Paganini-Hill A, Clark LJ: Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 60: 167–172, 2000PubMedGoogle Scholar
  8. 8.
    Yesavage JA, Brink TL, Rose TL, et al.: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiat Res 17: 37–49, 1983Google Scholar
  9. 9.
    Freedman M, Leach L, Kaplan E, et al.: Clock Drawing: A Neuropsychological Analysis. Oxford University Press, New York, 1994Google Scholar
  10. 10.
    Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356–1364, 1984PubMedGoogle Scholar
  11. 11.
    Goodglass H, Kaplan E: The Assessment of Aphasia and Related Disorders. 2nd edition. Lea & Febiger, Philadelphia 1983, pp. 43–50Google Scholar
  12. 12.
    Watson YI, Arfken CL, Birge SJ: Clock completion: an objective screening test for dementia. J Am Geriatr Soc 41: 1235–1240, 1993PubMedGoogle Scholar
  13. 13.
    Henderson VW, Buckwalter JG, Sobel E, et al.: The agraphia of Alzheimer's disease. Neurology 42: 776–784, 1992Google Scholar
  14. 14.
    Breslow NE, Day NE: Statistical Methods in Cancer Research. Lyon, France: International Agency for Research on Cancer, 1987Google Scholar
  15. 15.
    Nussbaum PD, Fields RB, Starratt C: Comparison of three scoring procedures for clock drawing. Paper presented at the International Neuropsychological Society, San Diego, 1992Google Scholar
  16. 16.
    Libon DJ, Swenson R, Barnoski E, Sands LT: Clock drawing as an assessment tool in dementia. Arch Clin Neuropsychol 8: 405–416, 1993PubMedGoogle Scholar
  17. 17.
    Mendez MF, Ala T, Underwood KL: Development of scoring criteria for the clock drawing task in Alzheimer's disease. J Am Geriatr Soc 40: 1095–1099, 1992PubMedGoogle Scholar
  18. 18.
    Tuokko H, Hadjistavropoulos T, Miller JA, Beattie BL. The clock test: a sensitive measure to differentiate normal elderly from those with Alzheimer's disease. J Am Geriatr Soc 40: 579–584, 1992PubMedGoogle Scholar
  19. 19.
    Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K: Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain and Cognition 18: 70–87, 1992PubMedGoogle Scholar
  20. 20.
    Dastoor DP, Schwartz G, Kurzman D: Clock drawing - An assessment technique in dementia. J Clin Exp Gerontol 13: 69–85, 1991Google Scholar
  21. 21.
    Wolf-Klein GP, Silverstone FA, Levy AP, Brod MS, Breuer J: Screening for Alzheimer's disease by clock drawing. J Am Geriatr Soc 37: 730–734, 1989PubMedGoogle Scholar
  22. 22.
    Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafaman JH: Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc 37: 725–729, 1989PubMedGoogle Scholar
  23. 23.
    Ferrucci L, Cecchi F, Guralnik JM, Giampaoli S, Noce CL, Salani B, Bandinelli S, Baroni A for the FINE Study Group: Does the clock drawing test predict cognitive decline in older persons independent of the Mini-Mental State Examination? J Am Geriatr Soc 44: 1326–1331, 1996PubMedGoogle Scholar
  24. 24.
    Román GC, Royall DR: Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Disease and Assoc Disord 13(Suppl 3): S69–S80, 1999Google Scholar
  25. 25.
    Kirk A, Kertesz A. On drawing impairment in Alzheimer's disease. Arch Neurol 48: 73–77, 1991PubMedGoogle Scholar
  26. 26.
    Launer LJ, Wind AW, Deeg DJH: Nonresponse pattern and bias in a community-based cross-sectional study of cognitive functioning among the elderly. Am J Epidemiol 139: 803–812, 1994PubMedGoogle Scholar
  27. 27.
    Rouleau I, Salmon DP, Butters N: Longitudinal analysis of clock drawing in Alzheimer's disease patients. Brain Cogn 31: 17–34, 1996PubMedGoogle Scholar
  28. 28.
    Colsher PL, Wallace RB: Epidemiologic considerations in studies of cognitive function in the elderly: methodology and nondementing acquired dysfunction. Epidemiol Rev 13: 1–27, 1991PubMedGoogle Scholar
  29. 29.
    Sherwin BB: Estrogen effects on cognition in menopausal women. Neurology 48 (Suppl 7): S21–S26, 1997Google Scholar
  30. 30.
    Cathart CK, Jones SE, Pumroy CS, et al.: Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 27: 277–281, 1993PubMedGoogle Scholar
  31. 31.
    Shariff S, Cumming CE, Lees A, et al.: Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist. An expected or unexpected effect? Ann NY Acad Sci 761: 365–368, 1995PubMedGoogle Scholar
  32. 32.
    Wieneke MH, Dienst ER: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 4: 61–66, 1995Google Scholar
  33. 33.
    van Dam FSAM, Schagen SB, Muller MJ, et al.: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90: 210–218, 1998PubMedGoogle Scholar
  34. 34.
    Schagen SB, van Dam FSAM, Muller MJ, et al.: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85: 640–650, 1999PubMedGoogle Scholar
  35. 35.
    Jorm AF, Korten AE, Henderson AS: The prevalence of dementia: a quantitative integration of the literature. Acta psychiatr scand 76: 465–479, 1987PubMedGoogle Scholar
  36. 36.
    Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, D'Agostino RB, White LR: Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham study. Neurology 42: 115–119, 1992PubMedGoogle Scholar
  37. 37.
    Haynes B, Dowsett M: Clinical pharmacology of selective estrogen receptor modulators. Drugs and Aging 14: 323–336, 1999PubMedGoogle Scholar
  38. 38.
    Penotti M, Sironi L, Miglierina L, et al.: The effect of tamoxifen and transdermal 17β-estradiol on cerebral arterial vessels: a randomized controlled study. Am J Obstet Gynecol 178: 801–805, 1998PubMedGoogle Scholar
  39. 39.
    Nanda K, Bastian LA, Hasselblad V, Simel DL: Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 93: 880–888, 1999PubMedGoogle Scholar
  40. 40.
    Rutqvist LE, Johansson H, Signomklao T, et al.: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87: 645–651, 1995PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Annlia Paganini-Hill
    • 1
  • Linda J. Clark
    • 1
  1. 1.Department of Preventive MedicineKeck School of Medicine of the University of Southern CaliforniaLos AngelesUSA

Personalised recommendations